Brief: FDA Gives Positive Feedback For Anebulo's Aneb-001

Anebulo Pharmaceuticals

21/08/2023 13:14

Aug 21 (Reuters) - 
  
    * ANEBULO RECEIVES POSITIVE FEEDBACK FROM FDA ON PATH TO
ADVANCE
PHASE 3 CLINICAL DEVELOPMENT OF ANEB-001 AND COMPLETES DOSING OF
PHASE 2 EXTENSION
    * ANEBULO PHARMACEUTICALS INC - FDA PROVIDES FAVORABLE INPUT
ON
STUDIES TO SUPPORT ANEB-001 APPROVAL
    * ANEBULO PHARMACEUTICALS INC - PART C EXTENSION OF PHASE 2
TRIAL
COMPLETED EXPLORING THC CHALLENGE DOSE OF UP TO 60 MG
    * ANEBULO PHARMACEUTICALS INC - THC CHALLENGE DOSES OF 40 MG
AND
60 MG WERE WELL-TOLERATED WHEN DOSED IN COMBINATION WITH
ANEB-001
    * ANEBULO PHARMACEUTICALS - FULL SAFETY, PHARMACOKINETIC
,PHARMACODYNAMIC DATA FROM STUDY, AS WELL AS RESULTS AT HIGHER
DOSES OF THC, EXPECTED IN 4Q
    * ANEBULO PHARMACEUTICALS - IN ADDITION TO PART C EXTENSION,
OBSERVATIONAL PK STUDY IN PATIENTS REPORTING TO EMERGENCY
DEPARTMENT WITH ACI IS ONGOING

Source text for Eikon:  ID:nBw96tVlla 
Further company coverage:  ANEB.O 

 (Reporting by Abhinav Parmar)
 ((Reuters.Briefs@thomsonreuters.com;))